Usher Syndrome Type 2 Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major Usher syndrome type 2 markets reached a value of US$ 1.2 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 1.8 Billion by 2034, exhibiting a growth rate (CAGR) of 3.63% during 2024-2034.
The Usher syndrome type 2 market has been comprehensively analyzed in IMARC's new report titled "Usher Syndrome Type 2 Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Usher syndrome type 2 is a rare genetic disorder characterized by its dual impact on both hearing and vision. In this condition, the hearing loss is congenital and typically moderate to severe, making communication challenging from early childhood. The symptoms of the ailment manifest as a progressive loss of hearing and a gradual onset of vision problems. Individuals suffering from this syndrome may experience difficulties with speech and language development due to their hearing impairment. The visual deterioration is characterized by retinitis pigmentosa, a condition that leads to the degeneration of photoreceptor cells in the retina, causing night blindness and tunnel vision that worsen over time. The diagnosis of Usher syndrome type 2 involves a thorough assessment of both auditory and visual functions to help in determining the extent of hearing loss and the degree of retinal degeneration in patients. Genetic testing plays a crucial role in confirming the diagnosis by identifying mutations in genes associated with the disorder.
The escalating prevalence of mutations in the USH2A gene, which mainly leads to the dual sensory impairment of both hearing and vision, is primarily driving the Usher syndrome type 2 market. In addition to this, the inflating utilization of hearing aids and cochlear implants, supported by advancements in auditory technology, is also creating a positive outlook for the market. These devices aid in mitigating the hearing loss component of the syndrome, thereby enabling better communication and interaction with the surrounding environment. Moreover, the widespread adoption of physical and orientation mobility training to improve spatial awareness and navigation skills in individuals suffering from the ailment is further bolstering the market growth. Apart from this, the rising usage of telemedicine for regular check-ups and consultations, since it offers a more accessible approach to disease management, is acting as another significant growth-inducing factor. Additionally, the increasing application of protein-based interventions that can effectively slow or prevent sensory deterioration in patients is also augmenting the market growth. Furthermore, the emerging popularity of innovative treatments encompassing gene augmentation therapy, which involves introducing functional genetic material to replace or rectify mutated genes, is expected to drive the Usher syndrome type 2 market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the Usher syndrome type 2 market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Usher syndrome type 2 and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Usher syndrome type 2 market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the Usher syndrome type 2 market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the Usher syndrome type 2 market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current usher syndrome type 2 marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the Usher syndrome type 2 market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the Usher syndrome type 2 market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the Usher syndrome type 2 market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of Usher syndrome type 2 across the seven major markets?
What is the number of prevalent cases (2018-2034) of Usher syndrome type 2 by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of Usher syndrome type 2 by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with Usher syndrome type 2 across the seven major markets?
What is the size of the Usher syndrome type 2 patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of Usher syndrome type 2?
What will be the growth rate of patients across the seven major markets?
Usher Syndrome Type 2: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for Usher syndrome type 2 drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Usher syndrome type 2 market?
What are the key regulatory events related to the Usher syndrome type 2 market?
What is the structure of clinical trial landscape by status related to the Usher syndrome type 2 market?
What is the structure of clinical trial landscape by phase related to the Usher syndrome type 2 market?
What is the structure of clinical trial landscape by route of administration related to the Usher syndrome type 2 market?
The Usher syndrome type 2 market has been comprehensively analyzed in IMARC's new report titled "Usher Syndrome Type 2 Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Usher syndrome type 2 is a rare genetic disorder characterized by its dual impact on both hearing and vision. In this condition, the hearing loss is congenital and typically moderate to severe, making communication challenging from early childhood. The symptoms of the ailment manifest as a progressive loss of hearing and a gradual onset of vision problems. Individuals suffering from this syndrome may experience difficulties with speech and language development due to their hearing impairment. The visual deterioration is characterized by retinitis pigmentosa, a condition that leads to the degeneration of photoreceptor cells in the retina, causing night blindness and tunnel vision that worsen over time. The diagnosis of Usher syndrome type 2 involves a thorough assessment of both auditory and visual functions to help in determining the extent of hearing loss and the degree of retinal degeneration in patients. Genetic testing plays a crucial role in confirming the diagnosis by identifying mutations in genes associated with the disorder.
The escalating prevalence of mutations in the USH2A gene, which mainly leads to the dual sensory impairment of both hearing and vision, is primarily driving the Usher syndrome type 2 market. In addition to this, the inflating utilization of hearing aids and cochlear implants, supported by advancements in auditory technology, is also creating a positive outlook for the market. These devices aid in mitigating the hearing loss component of the syndrome, thereby enabling better communication and interaction with the surrounding environment. Moreover, the widespread adoption of physical and orientation mobility training to improve spatial awareness and navigation skills in individuals suffering from the ailment is further bolstering the market growth. Apart from this, the rising usage of telemedicine for regular check-ups and consultations, since it offers a more accessible approach to disease management, is acting as another significant growth-inducing factor. Additionally, the increasing application of protein-based interventions that can effectively slow or prevent sensory deterioration in patients is also augmenting the market growth. Furthermore, the emerging popularity of innovative treatments encompassing gene augmentation therapy, which involves introducing functional genetic material to replace or rectify mutated genes, is expected to drive the Usher syndrome type 2 market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the Usher syndrome type 2 market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Usher syndrome type 2 and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Usher syndrome type 2 market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the Usher syndrome type 2 market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the Usher syndrome type 2 market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current usher syndrome type 2 marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the Usher syndrome type 2 market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the Usher syndrome type 2 market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the Usher syndrome type 2 market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of Usher syndrome type 2 across the seven major markets?
What is the number of prevalent cases (2018-2034) of Usher syndrome type 2 by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of Usher syndrome type 2 by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with Usher syndrome type 2 across the seven major markets?
What is the size of the Usher syndrome type 2 patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of Usher syndrome type 2?
What will be the growth rate of patients across the seven major markets?
Usher Syndrome Type 2: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for Usher syndrome type 2 drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Usher syndrome type 2 market?
What are the key regulatory events related to the Usher syndrome type 2 market?
What is the structure of clinical trial landscape by status related to the Usher syndrome type 2 market?
What is the structure of clinical trial landscape by phase related to the Usher syndrome type 2 market?
What is the structure of clinical trial landscape by route of administration related to the Usher syndrome type 2 market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 USHER SYNDROME TYPE 2 - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 USHER SYNDROME TYPE 2 - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 USHER SYNDROME TYPE 2 - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 USHER SYNDROME TYPE 2 - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 USHER SYNDROME TYPE 2 - UNMET NEEDS
10 USHER SYNDROME TYPE 2 - KEY ENDPOINTS OF TREATMENT
11 USHER SYNDROME TYPE 2 - MARKETED PRODUCTS
11.1 List of Usher Syndrome Type 2 Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 USHER SYNDROME TYPE 2 - PIPELINE DRUGS
12.1 List of Usher Syndrome Type 2 Pipeline Drugs Across the Top 7 Markets
12.1.1 NT 501 - Neurotech Pharmaceutical
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Ultevursen - ProQR Therapeutics
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. USHER SYNDROME TYPE 2 - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. USHER SYNDROME TYPE 2 – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 USHER SYNDROME TYPE 2 - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Usher Syndrome Type 2 - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Usher Syndrome Type 2 - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Usher Syndrome Type 2 - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Usher Syndrome Type 2 - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Usher Syndrome Type 2 - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Usher Syndrome Type 2 - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Usher Syndrome Type 2 - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Usher Syndrome Type 2 - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Usher Syndrome Type 2 - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Usher Syndrome Type 2 - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Usher Syndrome Type 2 - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Usher Syndrome Type 2 - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Usher Syndrome Type 2 - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Usher Syndrome Type 2 - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Usher Syndrome Type 2 - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Usher Syndrome Type 2 - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Usher Syndrome Type 2 - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Usher Syndrome Type 2 - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Usher Syndrome Type 2 - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Usher Syndrome Type 2 - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Usher Syndrome Type 2 - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Usher Syndrome Type 2 - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Usher Syndrome Type 2 - Access and Reimbursement Overview
16 USHER SYNDROME TYPE 2 - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 USHER SYNDROME TYPE 2 MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 USHER SYNDROME TYPE 2 MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 USHER SYNDROME TYPE 2 - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 USHER SYNDROME TYPE 2 - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 USHER SYNDROME TYPE 2 - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 USHER SYNDROME TYPE 2 - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 USHER SYNDROME TYPE 2 - UNMET NEEDS
10 USHER SYNDROME TYPE 2 - KEY ENDPOINTS OF TREATMENT
11 USHER SYNDROME TYPE 2 - MARKETED PRODUCTS
11.1 List of Usher Syndrome Type 2 Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 USHER SYNDROME TYPE 2 - PIPELINE DRUGS
12.1 List of Usher Syndrome Type 2 Pipeline Drugs Across the Top 7 Markets
12.1.1 NT 501 - Neurotech Pharmaceutical
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Ultevursen - ProQR Therapeutics
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. USHER SYNDROME TYPE 2 - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. USHER SYNDROME TYPE 2 – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 USHER SYNDROME TYPE 2 - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Usher Syndrome Type 2 - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Usher Syndrome Type 2 - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Usher Syndrome Type 2 - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Usher Syndrome Type 2 - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Usher Syndrome Type 2 - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Usher Syndrome Type 2 - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Usher Syndrome Type 2 - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Usher Syndrome Type 2 - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Usher Syndrome Type 2 - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Usher Syndrome Type 2 - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Usher Syndrome Type 2 - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Usher Syndrome Type 2 - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Usher Syndrome Type 2 - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Usher Syndrome Type 2 - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Usher Syndrome Type 2 - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Usher Syndrome Type 2 - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Usher Syndrome Type 2 - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Usher Syndrome Type 2 - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Usher Syndrome Type 2 - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Usher Syndrome Type 2 - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Usher Syndrome Type 2 - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Usher Syndrome Type 2 - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Usher Syndrome Type 2 - Access and Reimbursement Overview
16 USHER SYNDROME TYPE 2 - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 USHER SYNDROME TYPE 2 MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 USHER SYNDROME TYPE 2 MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
